Neutralizing activity – Page 21 – Communicable Diseases Research

Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China

HIV와 HIV 음성 개인 사이의 SARS-COV-2에 대한 비활성화 백신에 대한 면역 반응 비교 : 중국의 단면 연구

Comparative Study

Published on 2022-01-282022-09-01
Journal: Viruses [Category] 진단,

Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal

포르투갈에서 확인 된 SARS-COV-2의 고주파 돌연변이를 갖는 슈도 바이러스의 감염성 및 항원 성

Original Article

Published on 2022-01-272022-09-10
Journal: Archives of Virology [Category] COVID19(2023년), Fulltext, MERS, SARS, 변종, 진단,

[키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus antibodies antigenicity B.1.1.7 binding domain caused cell line coronavirus Cross-species transmission D614G Effectiveness Efficacy Epidemic epidemiological Epidemiological investigation evade evaluated hACE2 Health host immunity Huh7 immunized infect Infectivity monoclonal antibodies monoclonal antibody mouse serum mutant mutant strain Mutant strains mutants Mutation N439K N501Y neutralization activity Neutralizing activity nine overexpressing Portugal Prevalence Prevention and control pseudovirus pseudoviruses Receptor binding domain reduced Region regions respiratory S477N SARS-CoV-2 SARS-CoV-2 mutation severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly Spike protein Spread strain Strains supplementary material susceptible cell tested Vaccine Vaccines Variation Vero was performed was used weakened were used
[DOI] 10.1007/s00705-021-05327-0 PMC 바로가기 [Article Type] Original Article

SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron

SARS-CoV-2 스파이크 특이적 CD4+ T 세포 반응은 오미크론을 포함한 우려 변종에 대해 보존됩니다

Immunology

Published on 2022-01-262022-09-11
Journal: Frontiers in Immunology [Category] 변종,

[키워드] accumulating Administered Against Alpha Alpha variant antibody Antibody neutralization Beta CD4 CD4+ CD4+ T cell cellular immunity concern conserved country COVID-19 COVID-19 case COVID-19 cases Defense Delta Delta variants evade form Immunity Implications Including individual Infection investigated less majority memory memory response mRNA vaccination mutated natural infection Neutralizing activity observation omicron PROTECT Protein Region response responsible SARS-CoV-2 SARS-CoV-2 mutation SARS-CoV-2 variant spike Spike protein subject T cell T cell response T cells target Transmissibility vaccination vaccine dose variant variants variants of concern (VOCs) Wuhan strain
[DOI] 10.3389/fimmu.2022.801431 PMC 바로가기 [Article Type] Immunology

Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein

스파이크 당단백질에 대한 항체 반응의 도메인 특이성과 상대적 효능에서 SARS-CoV-2 감염 개인 간의 제한된 변이

Research Article

Published on 2022-01-262022-09-12
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adaptive immunity analyzed anti-spike antibodies anti-spike antibody antibodies antibody Antibody neutralization Antibody Response Antibody responses antiviral activity caused characterized collected composed convalescent convalescent-phase plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine defined domain domains Efficacy elicit elicited exhibited fixed form generate immunoassay immunoglobulins individual infected individual Limited MOST N-terminal domain neutralization neutralization potency neutralize Neutralizing activity Neutralizing antibodies NTD pandemic plasma samples polyclonal potency produced Protective pseudovirus quantity RBD Receptor-binding domain Region relative replication-competent SARS-CoV-2 response Sample SARS-CoV-2 SARS-CoV-2 spike serum serum and plasma Seven severe acute respiratory syndrome Coronavirus specificity spike glycoprotein Spike protein subject subjects subunit subunits tested the antibodies the antibody the antibody response the RBD the receptor-binding domain the Spike the spike protein trimer vaccinated individual Variability Variation virus while
[DOI] 10.1128/spectrum.02676-21 PMC 바로가기 [Article Type] Research Article

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

임상 과정은 감염 후 1년이 지난 후에도 SARS-CoV-2 중화 항체의 초기 동역학, 크기 및 진폭에 영향을 미칩니다.

Article

Published on 2022-01-242022-09-11
Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha amplitude B cell B cell memory B cells Beta boost both groups clinical coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 cross-neutralization activity determinant determinants Durability Efficacy evaluate expressing generate half-life Hospitalized humoral Humoral response identify immune responses Impact independent individual Infection long-term immune response long-term immune responses magnitude memory B cells mixed-effects models Multivariate analysis natural infection Neutralizing Neutralizing activity Neutralizing antibodies neutralizing responses participant Participants Patient plasma Primary infection prospective cohort pseudovirus pseudoviruses reduced respiratory response SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus severity symptom onset vaccination variants variants of concern
[DOI] 10.1016/j.xcrm.2022.100523 PMC 바로가기 [Article Type] Article

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

건강한 성인에게 2회 접종 불활화 백신을 접종한 후 3차 접종 바이러스 벡터 COVID-19 백신의 면역원성

Article

Published on 2022-01-242022-09-11
Journal: Vaccine [Category] SARS, 변종, 진단,

[키워드] anti-RBD Anti-spike AZD1222 B.1.1.7 B.1.351 B.1.617.2 booster booster dose completion CoronaVac COVID-19 COVID-19 vaccine delta variant demonstrated dose elicited enzyme enzyme-linked immunosorbent healthcare worker Healthcare workers healthy IgA IgG immune response immunogenicity Immunoglobulin immunoglobulins Inactivated vaccine Inactivated Vaccines individual neutralization test neutralizing activities Neutralizing activity participant Protein Public public health RBD RBD-specific IgG receiving recipient recipients resulting SARS-CoV-2 SARS-CoV-2 spike sera serum sample serum samples subset surrogate virus neutralization test tested Vaccine vaccinee Vaccines variant variant of SARS-CoV-2 variants variants of concern virus neutralization test Virus vector widespread wild type
[DOI] 10.1016/j.vaccine.2021.11.083 PMC 바로가기 [Article Type] Article

The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections

Article

Published on 2022-01-242022-10-29
Journal: Scientific Reports [Category] Coronavirus,

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

합성 SARS-CoV-2 S 당단백질 바이러스 유사 입자로 면역화하여 원숭이를 감염으로부터 보호

Article

Published on 2022-01-242022-09-11
Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha anti-receptor-binding domain anti-S antibodies Antibody Response Antibody titer Antibody titers approach B cells Beta boost caused CD4 classical clinical testing coated Complete coronavirus COVID-19 cynomolgus macaque cynomolgus macaques formaldehyde formaldehyde cross-linking Gamma Health Health crisis IgA titers IgG Immunity immunization Immunoglobulin Immunoglobulin G induce Infection macaque macaques Nanoparticles nasopharyngeal Neutralizing activity pandemic predominant PROTECT protection Receptor-binding domain receptor-binding domains respiratory S glycoprotein Safe SARS-CoV-2 SARS-CoV-2 S glycoprotein SARS-CoV-2 spike severe acute respiratory syndrome Coronavirus sterilizing immunity T cell T cell responses T helper the vaccine trimer vaccine candidate vaccine strain variant Vesicle Virus-like particle virus-like particles
[DOI] 10.1016/j.xcrm.2022.100528 PMC 바로가기 [Article Type] Article

An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward

정신과 폐쇄 병동에서 SARS-CoV-2 델타 변종에 의한 획기적인 감염 발생

Article

Published on 2022-01-242022-09-11
Journal: Journal of Korean medical science [Category] 변종, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 breakthrough Breakthrough infection breakthrough infections caused ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Clinical data coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 diagnosis COVID-19 outbreak Delta delta variant demographic dose duration of hospitalization Epidemic highlight hospital Hospitalization Immunity index case infecting information less Neutralizing activity occurred outbreak Patient PCR test prevalent Prevent Prolonged Psychiatric Psychiatric Hospital reduce mortality reported SARS-CoV-2 SARS-CoV-2 Delta variant SARS-CoV-2 PCR test SARS-CoV-2 PCR test results second vaccination severe acute respiratory syndrome Coronavirus Spread the SARS-CoV-2 vaccination Vaccine vaccinee vaccinees variant ward
[DOI] 10.3346/jkms.2022.37.e28 PMC 바로가기 [Article Type] Article

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

mRNA-1273 및 BNT162b2 mRNA 백신은 SARS-CoV-2 오미크론 변이체에 대한 중화 활성을 감소시켰습니다

Article

Published on 2022-01-242022-09-11
Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody B.1.1.529 BNT162b2 mRNA vaccine booster booster dose coronavirus dose doses Immunity individual initial live-virus majority mRNA mRNA vaccines mRNA-1273 Mutation naïve individuals neutralization neutralization activity Neutralization assay Neutralizing activity Neutralizing antibody response neutralizing antibody responses observé omicron Omicron variant receiving reduced reduction reduction in required respiratory robust SARS-CoV-2 sera serum severe acute respiratory syndrome Coronavirus subject the SARS-CoV-2 vaccination Vaccinations Vaccine vaccine induced immunity.
[DOI] 10.1016/j.xcrm.2022.100529 PMC 바로가기 [Article Type] Article